Skip to main content
. 2026 Aug 3;16:1911851. doi: 10.3389/fonc.2026.1911851

Figure 2.

Panel of six CT scan slices labeled A through F with red arrows in the top row (A–C) and green arrows in the bottom row (D–F), pointing to lymph node regions in the neck and upper chest across axial, coronal, and sagittal planes for comparative visualization.

Radiologic changes in the left supraclavicular target lymph node before and after treatment. (A–C) Pretreatment contrast-enhanced CT images showing the left supraclavicular target lymph node measuring 22 × 18 mm, with a short-axis diameter of 18 mm. (D–F) Follow-up CT images obtained after four cycles of carboplatin, nab-paclitaxel, and tislelizumab showing that the lymph node had decreased to 22 × 7 mm, with a short-axis diameter of 7 mm, representing a 61.1% reduction in the short-axis diameter from baseline.